Last C$0.24 CAD
Change Today +0.01 / 4.44%
Volume 2.0K
MOM On Other Exchanges
As of 9:53 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

miraculins inc (MOM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/13 - C$0.85
52 Week Low
04/9/14 - C$0.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MIRACULINS INC (MOM)

Related News

No related news articles were found.

miraculins inc (MOM) Related Businessweek News

No Related Businessweek News Found

miraculins inc (MOM) Details

Miraculins Inc., a medical diagnostic company, focuses on acquiring, development, and commercialization of non-invasive technologies for unmet clinical needs in Canada. The company's PreVu non-invasive skin cholesterol test, a coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin; and SCOUT DS system, a non-invasive diabetes screening system designed to provide sensitive and convenient method for screening for pre-diabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin. It also develops preeclampsia diagnostic test for preeclampsia, a pregnancy specific disease; and offers testing services. The company was incorporated in 1998 and is headquartered in Winnipeg, Canada.

Founded in 1998

miraculins inc (MOM) Top Compensated Officers

Chief Executive Officer, President and Non In...
Total Annual Compensation: C$219.6K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

miraculins inc (MOM) Key Developments

Miraculins Inc. Auditor Raises 'Going Concern' Doubt

Miraculins Inc. filed its Annual on Mar 28, 2014 for the period ending Nov 30, 2013. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Miraculins Inc. Announces Board Changes

Miraculins Inc. announced the resignation of Lisa Suennen from the Miraculins Board of Directors, and the appointment in her place of David A. Eichler. Ms. Suennen was appointed to the Miraculins Board in connection with the closing of the transaction that resulted in Miraculins acquiring the Scout DS(R) diabetes testing technology from Veralight Inc. At the time, Ms. Suennen was a partner of Psilos Group which is the majority shareholder of Veralight, and also served as Chair of Veralight's Board of Directors. Her recently announced departure from Psilos Group has accordingly resulted in her resignation from the Miraculins Board. Replacing Ms. Suennen will be David A. Eichler, who is a Managing Member of Psilos Group. Mr. Eichler joined Psilos in 1999 and focuses primarily on investments in the medical technology and healthcare services sectors. Currently, Mr. Eichler serves on the board of Veralight and also as Chairman of the Board of Caregiver Services Inc. and Gamma Medica Inc.

Miraculins Inc. Appoints Cachet Pharmaceutical Co., Ltd. as Exclusive Chinese Distributor for Scout DS Diabetes Test

Miraculins Inc. announced that it has executed a term sheet with Cachet Pharmaceutical Co., Ltd. to appoint Cachet as the exclusive Chinese distributor for the Scout DS Non-Invasive Diabetes Screening Test. The Term Sheet has now established the principal terms and conditions of the proposed distribution agreement between Miraculins and Cachet for China, including Scout DS device unit pricing, upfront and milestone payments, product ordering and diligence requirements, and ongoing responsibilities of the parties. The term of the Agreement would extend for five years from the date of CFDA clearance, subject to minimum annual order quantities by Cachet. If minimum orders were met, this would represent an additional order value of $75 million in Scout DS device orders over the length of the term. Miraculins would be responsible for leading the CFDA clearance process and its related costs. Cachet would provide guidance annd support for the process as necessary. Scout DS has received regulatory clearance in Canada and throughout the European Union. Upon clearance of the Scout DS in China, Cachet would be responsible for all sales and marketing costs. Miraculins would provide sales and marketing guidance and support as required and would provide a limited number of not-for-sale devices to Cachet for use in market development activities. Miraculins would retain the right to establish programs for ongoing device servicing and maintenance once the Scout DS devices are sold into the field.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOM:CN C$0.24 CAD +0.01

MOM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Diagnocure Inc C$0.19 CAD 0.00
Health Discovery Corp $0.03 USD -0.003
Imperial Innovations Group PLC 447.50 GBp -5.00
MDxHealth €4.30 EUR +0.004
Vermillion Inc $2.82 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation MOM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.9x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIRACULINS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at